E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Breast cancer is the most frequently diagnosed malignancy and the second most common cause of cancer related deaths in women. HER2 is a member of the epidermal growth factor receptor (EGFR) family that includes EGFR/HER1, HER2, HER3 and HER4, all being receptor tyrosine-protein kinases. The oncogenic role of HER2 has been extensively documented in breast cancer, where it is overexpressed in 25% to 30% of breast cancers. |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Determine the sixteen (16) week progression-free survival (PFS) rate for HKI-272 in women with advanced breast cancer. |
|
E.2.2 | Secondary objectives of the trial |
· Further evaluate the safety of HKI-272 · Assess additional efficacy parameters: objective response rate, clinical benefit rate (CR +PR +SD), duration of response. · Assess health outcomes endpoints by administering quality of life questionnaires · Evaluate the pharmacokinetics of HKI-272 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Pathologic diagnosis of breast cancer and current stage IIIB, IIIC, or IV breast cancer not curable with available therapy. 2. Progression following at least six weeks of standard doses of Herceptin (trastuzumab) or a Herceptin containing regimen in a metastatic or locally advanced setting; or progression on or following Herceptin containing adjuvant therapy (Arm A only). Up to 20 subjects with HER2+ breast cancer with prior lapatinib exposure may be enrolled in ARM A only. 3. Tumor tissue available and adequate for HER2 gene amplification. 4. HER2 gene amplified tumor by FISH (fluorescence in situ hybridization). 5. At least 1 measurable lesion as defined by modified RECIST criteria. 6. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 (not declining within past 2 weeks). 7. Women aged >= 18 years. 8. Life expectancy of at least 12 weeks. 9. Recovery from all clinically significant acute adverse effects of prior therapies (excluding alopecia). 10. Screening laboratory values within the following parameters: ANC >= 1.5 x 10^9/L (1,500/mm^3) Platelet count >= 75 x 10^9/L (75,000/mm^3) Hemoglobin >= 8.0 g/dL (80g/L) Serum creatinine <= 1.5 x upper limit of normal (ULN) Total bilirubin <= 1.5 x ULN AST and ALT <= 2.5 x ULN (<= 5 x ULN if liver metastases are present) 11. For women of child bearing potential, a negative serum pregnancy test result before study entry. A woman of child bearing potential is one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or whose sexual partners are either sterile or are using contraceptives. 12. Willingness of female subjects, who are not surgically sterile or postmenopausal, to use medically acceptable methods of birth control for the duration of the study and for 28 days after the last dose of test article. |
|
E.4 | Principal exclusion criteria |
1. Prior treatment with Herceptin or any HER2-targeted treatment (Arm B only) 2. More than 4 prior cytotoxic chemotherapy treatment regimens for relapsed or metastatic disease. 3. Major surgery, chemotherapy, radiotherapy, investigational agents or other cancer therapy within 1 week of treatment day 1. 4. Extensive visceral disease including bilateral diffuse lymphangitic involvement of the lung with more than 50% lung involvement, extensive hepatic involvement defined as involvement of more than one third of the liver confirmed by CT or MRI scan. 5. Subjects with bone or skin as the only site of measurable disease 6. Active central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (subjects with a history of CNS metastases or cord compression are allowable if they have been definitively treated and are clinically stable for at least 4 weeks before first dose of test article). 7. History of clinically significant or uncontrolled cardiac disease, including congestive heart failure (New York Heart Association [NYHA] functional classification of >=3), angina, myocardial infarction, or ventricular arrhythmia. 8. Left ventricular ejection fraction less than 50% measured by multigated blood pool imaging of the heart (MUGA) scanning or echocardiogram (ECHO) 9. QTc interval > 0.47 second 10. Prior treatment with anthracyclines with a cumulative dose of doxorubicin or equivalent > 400 mg/m^2 11. Pregnant or breast feeding women 12. Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom (e.g, Crohn’s disease, malabsorption, or Grade >=2 diarrhea of any etiology at baseline) 13. Inability or unwillingness to swallow the HKI-272 capsules 14. Evidence of significant medical illness or abnormal laboratory finding that would, in the investigator’s judgment, make the subject inappropriate for this study. Examples include, but are not limited to, serious active infection (i.e. requiring intravenous antibiotic or antiviral agent), uncontrolled major seizure disorder, any other active malignancy (except for breast cancer). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Clinical activity will be assessed using the primary endpoint of 16 week Progression-Free Survival (PFS) rate. Progression status will be determined using modified RECIST guidelines. The primary efficacy analysis will be based on the intent-to-treat (ITT) and evaluable populations. The ITT population is defined as all subjects enrolled in the study. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |